SCHEMBL4773300

SCHEMBL4773300

O=C(O)CCCNC(=O)c1ccc(NS(=O)(=O)CCc2cccc(Cl)c2Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
KMT2A Q03164 1/20 0.44
MAPK1 P28482 1/20 0.44
HIF1A Q16665 1/20 0.44
EPHX2 P34913 2/20 0.43
HDAC6 Q9UBN7 1/20 0.42
FABP4 P15090 1/20 0.42
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GCG P01275 1/20 0.40
LMNA P02545 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773260 0.90 L3MBTL1 (0.44) CA1CA2L3MBTL1KMT2AHIF1A
SCHEMBL4773304 0.89 ALDH1A1 (0.44) CA1CA2L3MBTL1KMT2AHIF1A
SCHEMBL4776821 0.89 L3MBTL1 (0.43) CA1CA2L3MBTL1KMT2AHIF1A
SCHEMBL4768057 0.88 L3MBTL1 (0.43) CA1CA2L3MBTL1KMT2AHIF1A
SCHEMBL4773486 0.88 L3MBTL1 (0.43) CA1CA2L3MBTL1KMT2AHIF1A
SCHEMBL4773557 0.88 L3MBTL1 (0.43) CA1CA2L3MBTL1KMT2AHIF1A
SCHEMBL4777421 0.88 L3MBTL1 (0.43) CA1CA2L3MBTL1KMT2AHIF1A
SCHEMBL4777299 0.87 L3MBTL1 (0.46) CA1CA2L3MBTL1KMT2AHIF1A
SCHEMBL4793315 0.87 ALDH1A1 (0.43) CA1CA2ALDH1A1GAA
SCHEMBL4767750 0.87 HDAC6 (0.44) CA2L3MBTL1KMT2AHIF1AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 CA1 3116/4885CA2 2238/4885L3MBTL1 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.